| Sonstiges: |
- Nachgewiesen in: USPTO Patent Applications
- Sprachen: English
- Document Number: 20230118252
- Publication Date: April 20, 2023
- Appl. No: 17/906211
- Application Filed: April 01, 2021
- Assignees: Qualisure Diagnostics Inc. (Calgary, AB, CA)
- Claim: 1-30. (canceled)
- Claim: 31. A method of determining a risk of recurrence of a papillary thyroid cancer (PTC) in a patient, the method comprising: (a) isolating RNA from a biological sample of the patient; (b) determining a level of expression of each of two or more genes or gene products of a gene signature from the RNA, the gene signature comprising: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, HIST4H4, CENPL, GATAD1, C2orf88, WWC3, SKA3, HJURP, LOC728613, GTPBP8, RPRM, FBXO4, TICRR, AGFG2, TTK, TAFA2, MTMR14, WDR1, NEK2, RRAGA, EIF2A, REP15, NUDT15, LANCL2, NFATC2IP, GTPBP2, KHNYN, CLDN12, DNAH11, ASPHD1, REXO5, HIST2H2BF, C12orf76, MUC21, PGBD5, ABCC6P1, RHBDF1, CHAF1B, MOV10, CAB39L, FN1, DDX19B, BUB1, GPSM2, MSH5, ETV7, SUN1, GRAMD1C, LACTB2, LOC652276, EXOSC10, NUP210, ACOX3, UNC5CL, GNAO1, CGN, ZC3H18, CTSC, MFSD13A, and CCDC183; and (c) determining if the patient has a low risk, an intermediate risk, or a high risk of recurrence of PTC based on the level of expression of the two or more genes of the gene signature.
- Claim: 32. The method of claim 31, wherein the biological sample is: obtained by macrodissection or microdissection of a tumor; a formalin-fixed paraffin embedded (FFPE) tumor sample; a frozen biopsy tumor sample; a tumor sample that is obtained by fine-needle aspiration; a tumor sample that is obtained by a core biopsy; a tumor sample that is obtained by from a surgical specimen; or any combination thereof.
- Claim: 33. The method of claim 31, wherein the step of determining of the level of gene expression comprises measuring the level of gene expression using a reverse-transcription polymerase chain reaction (RT-PCR), a complimentary deoxyribonucleic acid (cDNA) microarray, or a ribonucleic acid sequencing (RNAseq).
- Claim: 34. The method of claim 31, wherein the step of determining the level of expression of the two or more genes or gene products of the gene signature comprises determining the level of expression of 5 or more genes of the gene signature.
- Claim: 35. The method of claim 34, wherein the step of determining the level of expression of the two or more genes or gene products of the gene signature comprises determining the level of expression of between 20 to 60 genes of the gene signature.
- Claim: 36. The method of claim 31, wherein: the step of determining the level of expression of the two or more genes of the gene signature comprises determining the level of expression of at least two of: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, HIST4H4, CENPL, GATAD1, C2orf88, WWC3, SKA3, HJURP, LOC728613, GTPBP8, RPRM, FBXO4, TICRR, AGFG2, TTK, TAFA2, MTMR14, WDR1, NEK2, RRAGA, EIF2A, and REP15; and the step of determining the patient's risk of PTC recurrence comprises determining if the patient has a high risk of PTC recurrence.
- Claim: 37. The method of claim 36, wherein, if the patient is determined not to have a high risk of PTC recurrence, the method further comprises: determining the level of expression of at least two of the genes or gene products of the gene signature; and determining if the patient has an intermediate risk or a low risk of PTC recurrence.
- Claim: 38. The method of claim 31, wherein the step of determining the level of expression of the two or more genes or gene products of the gene signature comprises determining the level of expression of at least: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, NUDT15, LANCL2, NFATC2IP, GTPBP2, ZNF215, KHNYN, CLDN12, DNAH11, EZH2, ASPHD1, REXO5, HIST2H2BF, C12orf76, MUC21, PGBD5, ABCC6P1, RHBDF1, CHAF1B, MOV10, CAB39L, FN1, DDX19B, and BUB1.
- Claim: 39. The method of claim 31, wherein the step of determining if the patient has a low risk, an intermediate risk, or a high risk of recurrence of PTC recurrence comprises using a statistical model trained using the expression levels of the genes of the gene signature from a plurality of patients in combination with corresponding recurrence data of the plurality of patients.
- Claim: 40. A method of treating a patient having papillary thyroid cancer (PTC), the method comprising: (a) isolating RNA from a biological sample of the patient; (b) determining a level of expression of each of two or more genes of a gene signature from the RNA, the gene signature comprising: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, HIST4H4, CENPL, GATAD1, C2orf88, WWC3, SKA3, HJURP, LOC728613, GTPBP8, RPRM, FBXO4, TICRR, AGFG2, TTK, TAFA2, MTMR14, WDR1, NEK2, RRAGA, EIF2A, REP15, NUDT15, LANCL2, NFATC2IP, GTPBP2, KHNYN, CLDN12, DNAH11, ASPHD1, REXO5, HIST2H2BF, C12orf76, MUC21, PGBD5, ABCC6P1, RHBDF1, CHAF1B, MOV10, CAB39L, FN1, DDX19B, BUB1, GPSM2, MSH5, ETV7, SUN1, GRAMD1C, LACTB2, LOC652276, EXOSC10, NUP210, ACOX3, UNC5CL, GNAO1, CGN, ZC3H18, CTSC, MFSD13A, and CCDC183, (c) determining if the patient has a low risk, an intermediate risk, or a high risk of recurrence of PTC based on the level of expression of the two or more genes of the gene signature; and (d) administering a treatment to the patient based on the determined level of risk of PTC recurrence.
- Claim: 41. The method of claim 40, wherein the biological sample is: obtained by macrodissection or obtained by microdissection of a tumor; a formalin-fixed paraffin embedded (FFPE) tumor sample; a frozen biopsy tumor sample; a tumor sample that is obtained by fine-needle aspiration; a tumor sample that is obtained by a core biopsy; a tumor sample that is obtained by from a surgical specimen; or any combination thereof.
- Claim: 42. The method of claim 40, wherein the step of determining of the level of gene expression comprises measuring the level of gene expression using a reverse-transcription polymerase chain reaction (RT-PCR), a complimentary deoxyribonucleic acid (cDNA) microarray, or a ribonucleic acid sequencing (RNAseq).
- Claim: 43. The method of claim 40, wherein the step of determining the level of expression of the two or more genes of the gene signature comprises determining the level of expression of 5 or more genes of the gene signature.
- Claim: 44. The method of claim 40, wherein the step of determining the level of expression of the two or more genes of the gene signature comprises determining the level of expression of 20 to 60 genes of the gene signature.
- Claim: 45. The method of claim 40, wherein: the step of determining the level of expression of the two or more genes of the gene signature comprises determining the level of expression of at least two of: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, HIST4H4, CENPL, GATAD1, C2orf88, WWC3, SKA3, HJURP, LOC728613, GTPBP8, RPRM, FBXO4, TICRR, AGFG2, TTK, TAFA2, MTMR14, WDR1, NEK2, RRAGA, EIF2A, and REP15; and the step of determining the patient's risk of PTC recurrence comprises determining if the patient has a high risk of PTC recurrence.
- Claim: 46. The method of claim 40, wherein, if the patient is determined not to have a high risk of PTC recurrence, the method further comprises: determining the level of expression of at least two of the genes of the gene signature; and determining if the patient has an intermediate risk or a low risk of PTC recurrence.
- Claim: 47. The method of claim 40, wherein the step of determining the level of expression of the two or more genes of the gene signature comprises determining the level of expression of at least: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, NUDT15, LANCL2, NFATC2IP, GTPBP2, ZNF215, KHNYN, CLDN12, DNAH11, EZH2, ASPHD1, REXO5, HIST2H2BF, C12orf76, MUC21, PGBD5, ABCC6P1, RHBDF1, CHAF1B, MOV10, CAB39L, FN1, DDX19B, and BUB1.
- Claim: 48. The method of claim 40, wherein if the patient is determined to have a high risk of PTC recurrence, the treatment further comprises performing a total thyroidectomy, administering an adjuvant radioactive iodine (RAI) therapy, administering an immune checkpoint inhibitor, or a combination thereof and wherein, if the patient is determined to have an intermediate risk of PTC recurrence, the treatment comprises performing active surveillance, performing a hemithyroidectomy, administering an adjuvant radioactive iodine (RAI) therapy, or a combination thereof.
- Claim: 49. The method of claim 48, wherein the RAI therapy comprises a pre-treatment with an EZH2 inhibitor.
- Claim: 50. A method of determining a risk of recurrence of a papillary thyroid cancer (PTC) in a patient, the method comprising: (a) determining a level of expression of each of two or more genes or gene products of a gene signature from the RNA isolated from a biological sample of the patient, the gene signature comprising: ATG14, MYO3A, ERCC5, SLC43A1, ABCC8, LTK, COPS2, CCNA2, BNIP3, FAM86C1P, GNG4, GCFC2, EEF1A2, TXNL4B, SEPSECS, ZNF215, KIF4A, EZH2, CDCA8, DISP1, SNX29P2, ATP1B1, ZNF620, HIST4H4, CENPL, GATAD1, C2orf88, WWC3, SKA3, HJURP, LOC728613, GTPBP8, RPRM, FBXO4, TICRR, AGFG2, TTK, TAFA2, MTMR14, WDR1, NEK2, RRAGA, EIF2A, REP15, NUDT15, LANCL2, NFATC2IP, GTPBP2, KHNYN, CLDN12, DNAH11, ASPHD1, REXO5, HIST2H2BF, C12orf76, MUC21, PGBD5, ABCC6P1, RHBDF1, CHAF1B, MOV10, CAB39L, FN1, DDX19B, BUB1, GPSM2, MSH5, ETV7, SUN1, GRAMD1C, LACTB2, LOC652276, EXOSC10, NUP210, ACOX3, UNC5CL, GNAO1, CGN, ZC3H18, CTSC, MFSD13A, and CCDC183; and (b) determining if the patient has a low risk, an intermediate risk, or a high risk of recurrence of PTC based on the level of expression of the two or more genes of the gene signature.
- Current International Class: 12; 16; 16
|
